Clinical Treatment of Monkeypox

• 2025

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This webpage describes the clinical treatment of mpox, focusing on tecovirimat (TPOXX) as a potential treatment option. It explains that while there is no FDA-approved treatment for mpox, tecovirimat is available under an expanded access program for patients with severe cases or specific conditions. The document outlines eligibility criteria, dosage instructions, and possible side effects of tecovirimat. It also highlights ongoing studies to assess its effectiveness and safety in treating mpox. Additionally, it provides information on other treatments like brincidofovir and Vaccinia Immune Globulin (VIGIV).

---

Tags

Focus Area: Infectious Disease

Audiences: EMS Clinicians; Nurses; Physicians

Emergency Management Stage: Response

Keywords: Pain Management; Antiviral Agents; Clinical Trials as Topic; Monkeypox virus; Immunocompromised Host; Guidelines as Topic; Mpox (monkeypox)

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Fact Sheet: United States Response to the Clade I Mpox Outbreak in Several African Countries 2024 · Centers for Disease Control and Prevention (CDC) Clade I Monkeypox Outbreak Originating in Central Africa 2025 · Centers for Disease Control and Prevention (CDC) Clinical Considerations for Pregnant Women with Possible Zika Virus Infection 2024 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---